NASDAQ$LENZ
LENZ Therapeutics Inc · Q1 2026 earnings
Q1 2026 earnings ·
Briefing
LENZ Therapeutics reported Q1 2026 revenue of $1.9M and a net loss of $41.5M, or $(1.32) per share.
For the quarter ended March 31, 2026, LENZ recorded $1.9 million in revenue, primarily license-related, versus none a year ago. The net loss was $41.5 million, or $(1.32) per diluted share, compared with a $14.6 million loss and $(0.53) per share in Q1 2025 as commercial and launch preparatory spend increased.
- First meaningful license revenue at $1.9M.
- Net loss widened to $41.5M on launch-related investment.
- Loss per share $(1.32) on higher operating spend.
- Pre-commercial ophthalmology company scaling for VIZZ.
Headline financials
Revenue & EPS history
LENZ Therapeutics Inc · Revenue · Quarterly
$1.9M
Forward guidance
Commercial launch trajectory for approved therapy will determine revenue ramp; spend elevated near term.
Tailwinds
- Initial revenue recognition from licensing.
- FDA-approved product entering commercial phase.
Headwinds
- Large quarterly loss ahead of full launch scale.
- Execution risk on commercial uptake.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 8 quarterly earnings reports · overlaid with Q1 2026
-2.8%
Avg return
Earnings day
-3.7%
Avg return
5 days after
-5.1%
Avg return
30 days after
20%
2 / 10 earnings
Positive
+5.0%
Q2 2022
Best reaction
-23.5%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +0.0% | -7.0% | — | |
| Q1 2026 | -0.8% | -27.1% | -34.5% | |
| Q3 2025 | -23.5% | -17.3% | -4.7% | |
| Q2 2025 | -2.9% | -7.4% | +22.0% | |
| Q3 2023 | -1.7% | -0.4% | -1.3% | |
| Q2 2023 | -4.5% | -4.5% | -17.4% | |
| Q1 2023 | -0.3% | -3.2% | -8.4% | |
| Q3 2022 | +1.9% | +7.1% | +1.9% | |
| Q2 2022 | +5.0% | +9.3% | -9.0% | |
| Q1 2022 | -0.9% | +13.9% | +5.2% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro